T.A.Z. Corp.
T.A.Z. Corporation is dedicated to combating antimicrobial resistance (AMR) by licensing and developing new antibiotics. They collaborate with scientists and organizations to bring innovative treatments through clinical trials, aiming to address the global crisis of resistant bacteria and contribute to the fight against antibiotic resistance.
Industries
Nr. of Employees
small (1-50)
Products
Licensed preclinical broad‑spectrum antibiotic program
A licensed preclinical antibiotic program reported to have broad-spectrum activity against both Gram-negative and Gram-positive bacteria, including priority ESKAPE pathogens; developed for translation from in vitro to in vivo models.
Licensed preclinical broad‑spectrum antibiotic program
A licensed preclinical antibiotic program reported to have broad-spectrum activity against both Gram-negative and Gram-positive bacteria, including priority ESKAPE pathogens; developed for translation from in vitro to in vivo models.
Services
Licensing of discovery-stage antibiotic projects and associated IP rights for defined territories to enable development by partner organizations.
Provision of funding and program management to advance licensed antibiotic projects from preclinical studies toward clinical trials.
Establishment of co-development arrangements and market-specific partnerships to support development and commercialization in target regions.
Design and operational support for global clinical trials in infectious diseases, including protocol development and trial oversight.
Licensing of discovery-stage antibiotic projects and associated IP rights for defined territories to enable development by partner organizations.
Provision of funding and program management to advance licensed antibiotic projects from preclinical studies toward clinical trials.
Establishment of co-development arrangements and market-specific partnerships to support development and commercialization in target regions.
Design and operational support for global clinical trials in infectious diseases, including protocol development and trial oversight.
Expertise Areas
- Antibiotic drug discovery
- Preclinical development and lead optimization
- Clinical development and global trial management
- Pharmacokinetics/pharmacodynamics (PK-PD) and translational science
Key Technologies
- Pharmacokinetic-pharmacodynamic (PK-PD) modeling
- In vitro infection models
- Animal infection models
- Antimicrobial susceptibility testing